Skip to main content

PhaseBio Pharmaceuticals Inc

PHASDelisted Dec 21, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001169245

PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding PhaseBio Pharmaceuticals Inc changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of PHAS: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders6256−6
Shares31.9M30.5M−1.42M (−4.5%)
Value$110.3M$113.3M+$3.01M (+2.7%)

New holders (13)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to PHAS in Q2 2021
InstitutionSharesValue% of portfolio
Candriam Luxembourg S.C.A.619,434$2.30M0.02%
Platform Technology Partners229,373$853.0K0.35%
Millennium Management LLC207,543$772.0K0.00%
Tibra Equities Europe Ltd91,200$339.0K0.10%
Ergoteles LLC69,800$260.0K0.01%
Resources Investment Advisors, LLC.52,450$195.0K0.01%
Cubist Systematic Strategies, LLC19,132$71.0K0.00%
D. E. Shaw & Co., Inc.17,674$66.0K0.00%
Occudo Quantitative Strategies LP14,915$55.0K0.01%
Parametric Portfolio Associates LLC10,254$38.0K0.00%
Captrust Financial Advisors521$2.00K0.00%
Simplex Trading, LLC517$1.00K0.00%
Point72 Hong Kong Ltd164$1.00K0.00%

Sold out (19)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q1 2021 and filed for Q2 2021 without it.